Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases
Diğer, ss.1-6, 2016
- Yayın Türü: Diğer Yayınlar / Diğer
- Basım Tarihi: 2016
- Sayfa Sayıları: ss.1-6
- İstanbul Üniversitesi Adresli: Evet
Özet
The present invention relates to the use of dasatinib or its pharmaceutically acceptable salts thereof as a potential pharmaceutical agent, more preferably anti-proliferative or anti-fibrotic agent in fibrotic lung diseases, in particular idiopathic pulmoner fibrosis (IPF) disease.